Panlong Pharmaceutical: PLJT-001 Loxoprofen Sodium Gel Patch has received the acceptance notice for domestic drug production registration and marketing license
Panlong Pharmaceutical recently announced that its research and development product, Loxoprofen Sodium Gel Patch (PLJT-001), has received the acceptance notice for the marketing authorization application from the National Medical Products Administration. This product is used to treat osteoarthritis, muscle pain, and swelling or pain after injury, with significant anti-inflammatory and analgesic effects, as well as low irritation and good skin compatibility, enhancing the comfort and convenience of medication
According to the Zhitong Finance APP, Panlong Pharmaceutical (002864.SZ) announced that its research product, Loxoprofen Sodium Gel Patch, has received the "Acceptance Notice" for the generic drug marketing authorization application issued by the National Medical Products Administration (referred to as "NMPA").
Loxoprofen Sodium Gel Patch (PLJT-001) is a gel patch used to treat osteoarthritis, muscle pain, and swelling or pain after injuries. The active ingredient in PLJT-001 is Loxoprofen Sodium, a non-steroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class, which has significant anti-inflammatory and analgesic effects, particularly strong analgesic effects. Its mechanism of action involves the inhibition of prostaglandin synthesis, with the action point being cyclooxygenase. Loxoprofen Sodium is a prodrug that, after transdermal absorption, is converted into the active metabolite trans-OH to exert its effects. This gel patch has low irritant allergenicity, strong adhesion that is not easily detached, a lightweight formulation with good skin extensibility, and can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience
